LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

LLY

714.52

-4.44%↓

JNJ

146.39

-1.44%↓

UNH

308.04

-0.79%↓

ABBV

177.11

-5.79%↓

NVO

64.32

-1.7%↓

Search

Avita Therapeutics Inc

Cerrado

6.71 -4.55

Resumen

Variación precio

24h

Actual

Mínimo

6.69

Máximo

7.16

Métricas clave

By Trading Economics

Ingresos

-2.3M

-14M

Ventas

108K

19M

BPA

-0.826

Margen de beneficios

-74.857

Empleados

260

EBITDA

-9.9M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+140.8% upside

Dividendos

By Dow Jones

Próximas Ganancias

7 ago 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-52M

192M

Apertura anterior

11.26

Cierre anterior

6.71

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Avita Therapeutics Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

14 may 2025, 23:40 UTC

Acciones populares

Stocks to Watch: UnitedHealth Group, Foot Locker, CoreWeave

14 may 2025, 23:33 UTC

Principales Movimientos del Mercado

UnitedHealth Group Shares Fall After WSJ Reports of Investigation for Possible Medicare Fraud

14 may 2025, 23:25 UTC

Principales Movimientos del Mercado

Biohaven Shares Down as FDA Extends PDUFA Data for Troriluzole

14 may 2025, 23:25 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 22:58 UTC

Ganancias

Xero Lifts Fiscal Year Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 21:35 UTC

Ganancias

Cisco Systems Names Patterson as CFO, Patel as President

14 may 2025, 23:59 UTC

Charlas de Mercado

Implications of Xero's Cost Outlook Aren't Clear -- Market Talk

14 may 2025, 23:49 UTC

Charlas de Mercado

Xero's Cost Outlook Likely to Prompt Downgrades -- Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

14 may 2025, 23:48 UTC

Charlas de Mercado

Nikkei May Decline on Profit-Taking After Recent Gains -- Market Talk

14 may 2025, 23:47 UTC

Charlas de Mercado

Gold Gains on Possible Technical Recovery -- Market Talk

14 may 2025, 23:34 UTC

Adquisiciones, fusiones, absorciones

Agnico-Eagle Mines to Subscribe for 30M Voting Common Shares of Foran Mining in Non-Brokered Private Placement at C$3 a Share

14 may 2025, 23:10 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth -- Update

14 may 2025, 23:07 UTC

Ganancias

CoreWeave Posts Strong Revenue and Wins Google as a Customer. Stock Still Dives on Outlook. -- Barrons.com

14 may 2025, 23:00 UTC

Principales Noticias

UnitedHealth Group Is Under Criminal Investigation for Possible Medicare Fraud -- WSJ

14 may 2025, 22:43 UTC

Ganancias

Xero Lifts FY Profit 30% on Higher Prices, Subscriber Growth

14 may 2025, 22:34 UTC

Ganancias

Xero Expects 1H Operating Expense Ratio to Be Higher Than 2H>XRO.AU

14 may 2025, 22:33 UTC

Ganancias

Xero Expects FY26 Operating Expense Ratio of 71.5%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero Did Not Declare a Dividend>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Operating Expenses 71.8% of Operating Revenue Vs. 73.3%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow Margin 24.1% Vs. 20.0%>XRO.AU

14 may 2025, 22:30 UTC

Ganancias

Xero FY Free Cashflow NZD506.7M Vs. NZD342.1M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Ebitda NZD638.5M Vs. NZD497.4M>XRO.AU

14 may 2025, 22:28 UTC

Ganancias

Xero FY Adjusted Ebitda NZD640.6M Vs. NZD526.5M>XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Rev NZD2.10B Vs. NZD1.71B >XRO.AU

14 may 2025, 22:27 UTC

Ganancias

Xero FY Net NZD227.8M Vs. Net NZD174.6M >XRO.AU

14 may 2025, 22:23 UTC

Principales Noticias

Boeing, GE Aerospace Get Qatar Airways Order After Saudi AI Tech Deals -- 2nd Update

14 may 2025, 22:15 UTC

Ganancias

Correction to Cisco Earnings Article -- WSJ

14 may 2025, 21:48 UTC

Ganancias

CoreWeave Posts Strong Revenue but Stock Dives on Updated Outlook -- Barrons.com

14 may 2025, 21:37 UTC

Ganancias

Cisco Reports Solid Earnings. The Stock Is Rising. -- Barrons.com

Comparación entre iguales

Cambio de precio

Avita Therapeutics Inc previsión

Precio Objetivo

By TipRanks

140.8% repunte

Estimación a 12 Meses

Media 16.88 USD  140.8%

Máximo 22 USD

Mínimo 12.5 USD

De acuerdo con 4 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Avita Therapeutics Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

4 ratings

4

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

8.83 / 9.77Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Weak Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Avita Therapeutics Inc

AVITA Medical, Inc., together with its subsidiaries, operates as a regenerative medicine company in the United States and internationally. The company's lead product is the RECELL System, a cell harvesting device used for the treatment of thermal burn wounds, full-thickness skin defects, and repigmentation of stable depigmented vitiligo lesions. It develops RECELL GO to control the manual process of disaggregation, filtration, and soak time. The company was formerly known as AVITA Therapeutics, Inc. AVITA Medical, Inc. was incorporated in 2020 and is headquartered in Valencia, California.